Excerpts

In contrast, male sex, allogeneic HSCT, hypertension, diabetes, BMI ≥ 25, and smoking were not independently associated, although hypertension showed a nonsignificant trend toward increased risk (OR 1.34; 95% CI 0.98–1.82; p = 0.07) ( Table 8 , Figure 4 ).

Regarding the diagnostic group, patients with primary tumors without axillary involvement showed a trend toward reduced recurrence risk (OR = 0.19, 95% CI: 0.03–1.47, p = 0.070), consistent with the expectation that localized disease has a more favorable prognosis.

Expression of miRNA-221 was not correlated with OS in the present patient cohort, however, in patients without neoadjuvant treatment miRNA-221 positive tumors showed a strong trend towards shortened OS ( p = 0.070) with a median OS of 64.0 months in miRNA-221 negative patients (95%CI not calculable) compared to a median OS of 22.1 month (95%CI 13.3–30.8 months).

CKD before treatment showed a trend towards a lower overall response rate (ORR, OR 0.5, p = 0.07) in multivariable analysis (MVA) and inferior relapse-free survival (RFS, HR 2.16, p = 0.06) in univariate analysis (UVA), but not MVA (RFS, HR 1.93, p = 0.15).

First, we looked at CR/CRi status at FU90 and found a trend for an association of chromatin-modifier mutations with a higher CR/CRi rate ( p = 0.07), whereas mutations in tumor-suppressor genes showed a trend for a lower CR/CRi rate ( p = 0.07) ( Supplementary Table S4 ).

Positive PD-L1 staining determined at a threshold of 1% showed a trend towards improved survival in the entire cohort (70.3% vs. 57.4%, p = 0.07) in univariate analysis ( Figure 2 ).

Furthermore, greater age was associated with worse KPS in POM3, with borderline significance, when controlled for other related variates (PRCC = −0.173, p = 0.070). 3.6.

On the contrary, among 157 patients undergoing adjuvant chemotherapy (a heterogeneous group of node-positive and/or pT4 and/or radically resected liver metastases patients; i.e., high-risk stage II patients and stage ≥ III cancers), MSS patients showed significantly better DFS rates (HR = 0.37; 95% CI 0.14–0.89; p = 0.005) and nearly significant OS rates (HR = 0.51; 95% CI 0.20–1.29; p = 0.07) than MSI patients, thus demonstrating that MSI tumors in advanced stages, requiring adjuvant therapy, are significantly disadvantaged or even harmed with conventional chemotherapy schedules ( Figure 2 and Figure 3 ). 3.2.

The FIGO stage was found to be of borderline significance ( p = 0.070, Figure 4 C).

Additionally, IGF1R mutations exhibited borderline significance (7.2% vs. 2.9%, p = 0.07).

Although alterations in PI3K, TGF-Beta, and RTK/RAS pathways were not statistically significant, borderline significance was observed in genes related to these pathways, including EGFR ( p = 0.07), FGFR1 ( p = 0.05), FGFR2 ( p = 0.05), and PTPN11 ( p = 0.05) in the PI3K pathway and SMAD4 ( p = 0.08) in the TGF-Beta pathway.

It seemed that AGEs and AGEs/sRAGE-ratio had a higher risk of breast cancer in premenopausal women than those postmenopausal women, and the interactions between AGEs and menopausal status were marginally significant ( p = 0.070).

However, the associations of N2c stage with OS (HR = 2.54 [95% CI = 1.21–5.33], p = 0.01) and PFS were statistically significant and marginally significant (HR = 1.93 [95% CI = 0.96–3.90], p = 0.07), respectively ( Table 3 ).

Regarding the LAD exposure, only the near maximum dose was significantly associated with increased CAC in LAD (OR = 1.04, p = 0.02), but this association was only marginally significant ( p = 0.07) in multivariate analysis. 4.

Additionally, though borderline significant, in patients that were diagnosed with pancreatic pathology at the age of 65 years or younger, COPD also correlated with IPMN (OR 4.4, 95% CI 0.98–19.79, p = 0.07).

There was, however, a trend towards significance between the PET and the CT data ( p -value = 0.070).

However, it is striking that nuclear/cytoplasmic expression of β-catenin has not been shown by itself in this meta-analysis to be significantly associated with poor survival, although a marked trend of effect is shown ( p = 0.07); this result is probably due to the paucity of primary studies addressing this question (3 studies, 255 patients).

The ypCR rate achieved was 25% versus 10.64% in favor of dose escalation, with no significant difference, but a trend toward significance ( p = 0.07).

The rate is markedly higher in patients with PSA > 0.15 ng/mL than in their counterparts with lesser PSA concentrations, but the difference only shows a possible trend toward statistical significance ( p = 0.07). 4.

Figure 5 B shows a statistical trend between a lower ADC value and PR or SD patients ( p = 0.07).

We observed a borderline significant link between G grade and recurrence ( p = 0.07) with a higher probability of recurrence for the G3 stage.

We found that there was a significant trend towards decreased OS rising from 1 to 2 to ≥3 sites involved (mOS 23.6 vs. 15.5 vs. 11.6 months respectively, p = 0.07). 4.

Patients with small lesions (maximum diameter <5 cm) showed a trend toward a higher OS rate ( p = 0.07).

In addition, the MoRAL score showed the best calibration function with a non-significant p value ( p = 0.15) by the Hosmer-Lemeshow test; the WCM model and the AFP model, the second and third best models evaluated by c -index, were found to be less accurate with marginally significant p values ( p = 0.07, and p = 0.06, respectively).

Analysis of microbiome variation in relation to spatial distance between sampled tissues revealed a strong trend toward significance ( p = 0.07) with a substantial effect size (R 2 = 0.207).